BioSpace News Archive

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of February 2023, which is payable on March 15, 2023 to shareholders of record at the close of business on February 28, 2023.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced updates on progress in the pre-clinical development program for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Galera Therapeutics, Inc. (Nasdaq: GRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review to the New Drug Application (NDA) for avasopasem manganese for radiotherapy (RT)-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC) undergoing standard-of-care treatment.

Corium Pharma Solutions, Inc., a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer.

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023.

Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners.

Mercy BioAnalytics, Inc. announced that Dawn Mattoon, PhD, has assumed the role of Chief Executive Officer and a member of the company’s Board of Directors, transitioning from her prior role as Chief Operating Officer as part of the company’s succession planning.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities.

Sesen Bio, Inc., announced that BML Investment Partners, L.P., one of Sesen Bio’s top stockholders, intends to vote all of its shares in support of the Company’s pending merger with Carisma Therapeutics Inc.

Anteris Technologies Ltd, a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece biomimetic aortic valve, announced the completion of a A$35M equity fundraising initiated on February 9th 2023.